We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

MINDRAY In-Vitro Diagnostics

As a global leader in in-vitro diagnostics, Mindray provides a wide range of efficient, reliable IVD solutions for la... read more Featured Products: More products

Download Mobile App




Platelet Indices Analyzed for Tuberculosis and Diabetes Mellitus Co-Morbidity

By LabMedica International staff writers
Posted on 03 Jun 2021
Print article
Image: The Mindray BC-6800 hematology analyzer (Photo courtesy of Shenzhen Mindray Bio-Medical Electronics)
Image: The Mindray BC-6800 hematology analyzer (Photo courtesy of Shenzhen Mindray Bio-Medical Electronics)
Studies have demonstrated that some diseases accelerate Tuberculosis (TB) occurrence and development. Type 2 diabetes mellitus (DM) has been verified as one of the threatening risk factors for TB, and patients have three times the risk of developing TB compared to non-diabetic patients due to pathogenic mechanisms and metabolic factors.

Platelets are enucleate cells and have critical roles in thrombosis, homeostasis and the inflammatory response. When the internal environment is changed, platelet morphology may be altered and play a role in certain platelet-associated parameters, mainly including platelet count (PC), plateletcrit (PCT), platelet distribution width (PDW) and mean platelet volume (MPV).

Clinical Laboratorians at Nantong University College of Medicine (Nantong, China) enrolled in a study 246 patients admitted to the hospital and were distributed into three groups (113 TB, 59 DM and 74 TB + DM). A total of 133 individuals were also recruited as healthy controls (HC). Platelet indices, namely, platelet count (PC), mean platelet volume (MPV), plateletcrit (PCT) and platelet distribution width (PDW), were compared among the four groups, and the relationship with inflammatory markers was explored by using statistical software.

TB diagnose was based on positive results of Xpert MTB/RIF (Cepheid Inc., Sunnyvale, CA, USA). The team used BACTEC MGIT 960 rapid liquid isolate culture (Becton Dickinson, Sparks, MD, USA), and the GenoType check system (Hain Lifescience, Nehren, Germany), and MTB smear confirmation by Ziehl-Neelsen acid-fast stain. Full blood counts were carried out using Mindray BC-6800 hematology analyzer (Shenzhen Mindray Bio-Medical Electronics Co. Ltd., Shenzhen, China). The Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were also measured.

The scientists reported that MPV and PCT were significantly downregulated in TB + DM patients (9.95 ± 1.25 fL, 0.20 ± 0.05%, separately) compared with DM individuals (10.92 ± 1.17 fL, 0.22 ± 0.04%). Moreover, the changes in MPV were significantly higher in TB + DM patients (9.95 ± 1.25 fL) than in TB patients (9.42 ± 1.01 fL). MPV improved the diagnosis sensitivity when it was combined with clinical parameters, such as fasting blood glucose in DM and Mycobacterium tuberculosis culture result in TB (76.3% versus 64.9%, 72.6% versus 60.8%), respectively. In addition, the sensitivity and specificity of PCT in the differential diagnosis of DM patients versus TB + DM patients were 69.5 and 59.4%, respectively. PCT improved the diagnosis sensitivity when combined with fasting blood glucose in DM (72.9% versus 64.9%). In addition, MPV was linked to CRP and ESR in the TB + DM patients.

The authors concluded that MPV is a valuable candidate marker to screen for TB-DM coinfection risk, as the occurrence of TB developing into TB-DM coinfection will increase MPV levels, and DM developing into a DM-TB coinfection will decrease MPV levels. MPV has significant specificity and sensitivity for predicting and diagnosing DM-TB coinfection. The study was published on May 20, 2021 in the journal BMC Infectious Diseases.

Related Links:
Nantong University College of Medicine
Cepheid Inc
Becton Dickinson
Hain Lifescience
Shenzhen Mindray


New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Total Thyroxine Assay
Total Thyroxine CLIA Kit
New
Nutating Mixer
Enduro MiniMix

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.